HeimHXB • FRA
add
AIM ImmunoTech Inc
Við síðustu lokun
6,10 €
Árabil
6,10 € - 22,00 €
Markaðsvirði
3,97 m. USD
V/H-hlutf.
-
A/V-hlutfall
-
Viðskiptafréttir
EBC Financial Group
fyrir 1 klukkustund
Dow Jones Index Today: When a Few Stocks Move the Whole Market
0,59%
0,63%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 21,00 þ. | -53,33% |
Rekstrarkostnaður | 2,93 m. | -50,23% |
Nettótekjur | -4,18 m. | 30,03% |
Hagnaðarhlutfall | -19,88 þ. | -49,93% |
Hagnaður á hvern hlut | -0,44 | 95,60% |
EBITDA | -2,91 m. | 49,77% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 3,05 m. | -23,38% |
Heildareignir | 5,78 m. | -32,83% |
Heildarskuldir | 15,56 m. | 56,75% |
Eigið fé alls | -9,78 m. | — |
Útistandandi hlutabréf | 8,15 m. | — |
Eiginfjárgengi | -1,91 | — |
Arðsemi eigna | -130,90% | — |
Ávöxtun eigin fjár | 171,11% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -4,18 m. | 30,03% |
Handbært fé frá rekstri | -1,99 m. | 49,79% |
Reiðufé frá fjárfestingum | -95,00 þ. | -102,56% |
Reiðufé frá fjármögnun | 2,72 m. | 162,20% |
Breyting á handbæru fé | 638,00 þ. | -18,83% |
Frjálst peningaflæði | -1,43 m. | 74,40% |
Um
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Stofnsett
1966
Höfuðstöðvar
Vefsvæði
Starfsfólk
20
